Oncoshot

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of p

Study number:: NCT06982521

Cohorts:: 1

Study phase:: 3, 2, 1

Overall status:: Recruiting

Study type:: Hormonal therapy, Targeted therapy

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

The purpose of this study is to evaluate evorpacept with anti-cancer therapies in advanced/metastatic malignancies. The study is comprised of the following substudies: * Metastati

Study number:: NCT07007559

Cohorts:: 1

Study phase:: 2

Overall status:: Recruiting

Study type:: Chemotherapy, Immunotherapy, Targeted therapy

A Study of ZW191 in Participants With Solid Tumors

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Study number:: NCT06555744

Cohorts:: 1

Study phase:: 1

Overall status:: Recruiting

Study type:: Targeted therapy

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor rec

Study number:: NCT06452277

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Targeted therapy

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous N

Study number:: NCT05910827

Cohorts:: 1

Study phase:: 1, 2

Overall status:: Recruiting

Study type:: Chemotherapy, Targeted therapy

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Study number:: NCT02633514

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Local/Regional therapies, Chemotherapy

Astrazeneca

Key trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investig

Study number:: NCT06103864

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Immunotherapy, Targeted therapy

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus part

Study number:: NCT05920356

Cohorts:: 1

Study phase:: 3

Overall status:: Not yet recruiting

Study type:: Chemotherapy, Targeted therapy

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for th

Study number:: NCT05696626

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Targeted therapy

Astrazeneca

Key trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer wit

Study number:: NCT05952557

Cohorts:: 1

Study phase:: 3

Overall status:: Recruiting

Study type:: Hormonal therapy